Pérez-Ayuso R M, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, Rodés J
Gastroenterology. 1983 May;84(5 Pt 1):961-8.
Loop and distal diuretics are the basic drugs for the treatment of ascites. Although pharmacologic studies indicate that the natriuretic potency of loop diuretics is much greater than that of distal diuretics, there are no studies comparing the efficacy of these drugs in cirrhosis. Forty nonazotemic cirrhotic patients with ascites and avid sodium retention were randomly allocated into two groups. Group 1 contained 21 patients treated with furosemide; group 2 contained 19 patients treated with spironolactone. The initial doses were 80 and 150 mg/day, respectively. These doses were increased to 160 and 300 mg/day, respectively, if there was no response. Cases not responding to furosemide and spironolactone were later treated with spironolactone and furosemide, respectively. In group 1, 11 of the 21 patients responded to furosemide, while in group 2, 18 of the 19 patients responded to spironolactone (p less than 0.01). Of the 10 patients in group 1 not responding to furosemide, 9 responded later to spironolactone. The diuretic response to furosemide and spironolactone was related to the activity of the renin-aldosterone system. Patients with higher renin and aldosterone did not respond to furosemide and required 300 mg/day of spironolactone to achieve a diuretic response. These results indicate that (a) at the dosages used in the study, spironolactone is more effective than furosemide in nonazotemic cirrhosis with ascites, and (b) the activity of the renin-aldosterone system influences the diuretic response to furosemide and spironolactone in these patients.
袢利尿剂和远曲小管利尿剂是治疗腹水的基本药物。尽管药理学研究表明袢利尿剂的利钠作用远大于远曲小管利尿剂,但尚无关于这些药物在肝硬化患者中疗效比较的研究。40例无氮质血症的肝硬化腹水患者,伴有明显的钠潴留,被随机分为两组。第1组21例患者接受呋塞米治疗;第2组19例患者接受螺内酯治疗。初始剂量分别为80mg/天和150mg/天。如果无反应,剂量分别增加至160mg/天和300mg/天。对呋塞米和螺内酯无反应的患者,随后分别改用螺内酯和呋塞米治疗。在第1组中,21例患者中有11例对呋塞米有反应,而在第2组中,19例患者中有18例对螺内酯有反应(P<0.01)。第1组中10例对呋塞米无反应的患者,9例后来对螺内酯有反应。对呋塞米和螺内酯的利尿反应与肾素-醛固酮系统的活性有关。肾素和醛固酮水平较高的患者对呋塞米无反应,需要300mg/天的螺内酯才能产生利尿反应。这些结果表明:(a)在本研究使用的剂量下,螺内酯在无氮质血症的肝硬化腹水中比呋塞米更有效;(b)肾素-醛固酮系统的活性影响这些患者对呋塞米和螺内酯的利尿反应。